Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Saturday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE BTX opened at $0.57 on Friday. The firm has a market cap of $33.30 million, a P/E ratio of -0.25 and a beta of 4.61. The stock’s 50-day moving average is $0.39 and its two-hundred day moving average is $1.07. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.